AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio - AbbVie News Center
Sentiment Mix
Geography
Expert Signals
Politics - Google News US Headlines
source • 2 mentions
AI-Generated Claims
Generated from linked receipts; click sources for full context.
AbbVie to Buy Immunology Drugmaker Apogee for $10.9 Billion - WSJ.
Supported by 1 story
AbbVie to Buy Immunology Drugmaker Apogee for $10.9 Billion WSJAbbVie Goes On The Offensive With $10.9 Billion Takeover Investor's Business DailyAbbVie inks $10.9B Apogee buyout to bag eczema prospect Fierce BiotechWhy AbbVie Is Spending $11 Billion to Buy Apogee Therapeutics—and Why the Stock Is Rising Barron'sAbbVie to buy Waltham's Apogee Therapeutics in nearly $11 billion deal The Boston Globe
Supported by 1 story
AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio AbbVie News CenterAbbVie to Buy Immunology Drugmaker Apogee for $10.9 Billion WSJDone deal: AbbVie to buy Apogee for $10.9B FirstWord PharmaAbbVie Goes On The Offensive With $10.9 Billion Takeover Investor's Business DailyAbbVie inks $10.9B Apogee buyout to bag eczema prospect Fierce Biotech
Supported by 1 story
Related Events
Confirmed Ebola cases in Congo outbreak top 1,000, with more than 250 deaths - NBC News
Uncategorized • 6/23/2026
Middle East cargo war premiums down by half in recent days, says DP World - Lloyd's List
Uncategorized • 6/22/2026
Province unveils findings of grocery price study - Winnipeg Free Press
Research • 6/23/2026
'Moral Hazard on Steroids': The Investor Who Called the Big Short Says Carney's Condo Bailout Is Worse Than 2008 Subprime Fiasco - The Bureau | Sam Cooper
Uncategorized • 6/22/2026
US authorizes Iranian oil sales amid talks on final peace deal - Reuters
Uncategorized • 6/22/2026